ACTRN12609000790246CompletedPhase 1
Phase I study of the maximum dose tolerability of carboplatin-irinotecan-paclitaxel combination (CIP) in patients with advanced refractory solid tumours
Hellenic Cooperative Oncology Group0 sites20 target enrollmentStarted: September 10, 2009Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to 75 Years (—)
- Sex
- All
Inclusion Criteria
- •Performance status: World Health Organization (WHO) 2 Life expectancy: At least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute neutrophil count at least 3,000/mm3 Absolute lymphocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Transaminase no greater than 2.5 times upper limit of normal Renal: Creatinine no greater than 1.4 mg/d
Exclusion Criteria
- •Cardiovascular: myocardial infarction within 6 months. Current, uncontrolled cardiac arrhythmias. History of anaphylactic reactions. Pregnancy. Serious uncontrolled, concurrent medical disorders.
Investigators
Similar Trials
Enrolling By Invitation
Phase 1
Engineered T cells for the treatment of B-cell leukemiaB-cell leukemiaCAR-CD19 T cellTCTR20160921001TCELS15
Enrolling By Invitation
Phase 1
K cells for the treatment of neuroblastomaHigh risk neuroblastomaNK cellNeuroblastomaTCTR20160918001TCELS15
Active, not recruiting
Phase 1
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a plasma cell tumor.Multiple myeloma in early relapse after intensive front line therapyMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2018-001741-14-ITOSPEDALE SAN RAFFAELE3
Active, not recruiting
Phase 1
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous systemGlioblastoma MultiformeEUCTR2018-001404-11-ITGENENTA SCIENCE SR21
Not yet recruiting
Not Applicable
GEN-001 multiple dose phase 1 studyKCT0006311Jeonbuk National University Hospital12